Nanoscale drug delivery for targeted chemotherapy

Cancer Letters

Volumn 379, Issue 1, 2016, Pages 24-31

  Xin, Yong ^a   Huang, Qian ^a   Tang, Jian Qin ^a   Hou, Xiao Yang ^a   Zhang, Pei ^a   Zhang, Long Zhen ^a   Jiang, Guan ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cancer therapy; Chemotherapy; Drug delivery system; Nanotechnology

Indexed keywords

DOXORUBICIN; LIPOSOME; NANOCARRIER; NANOPARTICLE; POLYMER; POLYMERIC MICELLE; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VERAPAMIL; ANTINEOPLASTIC AGENT; DRUG CARRIER;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; COLON CARCINOMA; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; DRUG TARGETING; GLIOMA; HUMAN; IMMUNOREGULATION; MELANOMA; MOUTH CARCINOMA; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SHORT SURVEY; SURFACE CHARGE; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; CHEMISTRY; DRUG FORMULATION; METABOLISM; NANOMEDICINE; NEOPLASMS; PATHOLOGY; PHARMACEUTICS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84971222811     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.05.023     Document Type: Review

References (102)

1. World Health Organization Global battle against cancer won't be won with treatment alone - effective prevention measures urgently needed to prevent cancer crisis. Cent. Eur. J. Public Health 2014, 22(1):23-28.
2. Dong X., Mumper R.J. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond.) 2010, 5(4):597-615.
3. Liu Z., Kiessling F., Gätjens J. Advanced nanomaterials in multimodal imaging: design, functionalization, and biomedical applications. J. Nanomater 2010, 2010. Article ID 894303.
4. Yang Y.Y., Yan Z.Q., Zhong J., He D.N., Lu W.Y. Peptide-mediated nano drug delivery system for tumor targeting. Prog. Chem 2013, 25(6):1052.
5. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov 2008, 7:771-782.
6. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev 1999, 51:691-743.
7. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
8. Rudokas M., Najlah M., Alhnan M.A., Elhissi A. Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications. Med. Princ. Pract 2016, Epub 2 Mar 2016. 10.1159/000445116.
9. Solomon R., Gabizon A.A. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin. Lymphoma Myeloma 2008, 8(1):21-32.
10. Hu C.-M.J., Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol 2012, 83:1104-1111.
11. Parhi P., Mohanty C., Sahoo S.K. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov. Today 2012, 17:1044-1052.
12. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303(5665):1818-1822.
13. Mastrobattista E., Koning G.A., Storm G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv. Drug Deliv. Rev 1999, 40(1-2):103-127.
14. Hong M.-S., Lim S.-J., Oh Y.-K., Kim C.-K. pH-sensitive, serum stable and long-circulating liposomes as a new drug delivery system. J. Pharm. Pharmacol 2002, 54:51-58.
15. van der Geest T., Laverman P., Gerrits D., Franssen G.M., Metselaar J.M., Storm G., et al. Comparison of three remote radiolabelling methods for long-circulating liposomes. J. Control. Release 2015, 220(Pt A):239-244.
16. Mohanraj V.J., Chen Y. Nanoparticles - a review. Trop. J. Pharm. Res 2006, 5(1):561-573.
17. Mainardes R.M., Evangelista R.C. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int. J. Pharm 2005, 290(1-2):137-144.
18. Gelperina S., Kisich K., Iseman M.D., Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am. J. Respir. Crit. Care Med 2005, 172(12):1487-1490.
19. Kreuter J. Nanoparticles as drug delivery system. Encyclopedia of Nanoscience and Nanotechnology 2004, vol. 7:161-180. American Scientific Publishers, New York.
20. Kedar U., Phutane P., Shidhaye S., Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine (Lond.) 2010, 6(6):714-729.
21. Liu Y., Li L.-L., Qi G.-B., Chen X.-G., Wang H. Dynamic disordering of liposomal cocktails and the spatio-temporal favorable release of cargoes to circumvent drug resistance. Biomaterials 2014, 35(10):3406-3415.
22. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 2001, 37:1590-1598.
23. Woodle M.C. Controlling liposome blood clearance by surface-grafted polymers. Adv. Drug Deliv. Rev 1998, 32:139-152.
24. Fadel M., Kassab K., Fadeel D.A. Zinc phthalocyanine-loaded PLGA biodegradable nanoparticles for photodynamic therapy in tumor-bearing mice. Lasers Med. Sci 2010, 25(2):283-292.
25. Nie G., Hah H.J., Kim G., Lee Y.E., Qin M., Ratani T.S., et al. Hydrogel nanoparticles with cova-lently linked coomassie blue for brain tumor delineation visible to the surgeon. Small 2012, 8(6):884-891.
26. He H., Li Y., Jia X.R., Ying X., Lu W.L., Lou J.N., et al. PEGylated poly(amidoamine) den-drimer-based dual-targeting carrier for treating brain tumors. Biomaterials 2011, 32(2):478-487.
27. Yan H., Wang J., Yi P., Lei H., Zhan C., Xie C., et al. Imaging brain tumor by dendrimer-based optical/paramagnetic nanoprobe across the blood-brain barrier. Chem. Commun. (Camb.) 2011, 47(28):8130-8132.
28. Faucher L., Guay-Begin A.A., Lagueux J., Côté M.F., Petitclerc E., Fortin M.A. Ultra-small gado-linium oxide nanoparticles to image brain cancer cells in vivo with MRI. Contrast Media Mol. Imaging 2011, 6(4):209-218.
29. Yan H., Wang L., Wang J., Weng X., Lei H., Wang X., et al. Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. ACS Nano 2012, 6(1):410-420.
30. Torchilin V.P., Lukyanov A.N., Gao Z., Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(10):6039-6044.
31. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release 2001, 73(2-3):137-172.
32. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin 2012, 62:10-29.
33. Liang X.J., Chen C., Zhao Y., Wang P.C. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol. Biol 2010, 596:467-488.
34. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol 2007, 2(12):751-760.
35. Shapira A., Livney Y.D., Broxterman H.J., Assaraf Y.G. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat 2011, 14(3):150-163. Review. 10.1016/j.drup.2011.01.003.
36. Hilgenbrink A.R., Low P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci 2005, 94:2135-2146.
37. Xu L.A., Pirollo K.F., Tang W.H., Rait A., Chang E.H. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum. Gene Ther 1999, 10:2941-2952.
38. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65(1):271-284.
39. Wang J., Sui M., Fan W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr. Drug Metab 2010, 11:129-141.
40. Cho K., Wang X., Nie S., Chen Z.G., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res 2008, 14:1310-1316.
41. Jabr-Milane L.S., van Vlerken L.E., Yadav S., Amiji M.M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev 2008, 34(7):592-602.
42. Hede S., Huilgol N. Nano: the new nemesis of cancer. J. Cancer Res. Ther 2006, 2(4):186-195.
43. Moghimi S.M., Hunter A.C., Murray J.C. Nanomedicine: current status and future prospects. FASEB J. 2005, 19(3):311-330.
44. Thornton G. Materials science. Watching nanoparticles grow. Science 2003, 300(5624):1378-1379.
45. Pokropivny V.V., Skorokhod V.V. New dimensionality classifications of nanostructures. Physica E Low Dimens. Syst. Nanostruct 2008, 40:2521-2525.
46. Wang K., Zhang X., Liu Y., Liu C., Jiang B., Jiang Y. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Biomaterials 2014, 35(30):8735-8747.
47. Xu Q., Liu Y., Su S., Li W., Chen C., Wu Y. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. Biomaterials 2012, 33(5):1627-1639.
48. Gao J., Chen H., Yu Y., Song J., Song H., Su X., et al. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA. Biomaterials 2013, 34(38):10084-10098.
49. Thorpe P.E., Chaplin D.J., Blakey D.C. The first international conference on vascular targeting: meeting overview. Cancer Res 2003, 63(5):1144-1147.
50. Su S., Wang H., Liu X., Wu Y., Nie G. iRGD-coupled responsive fluorescent nanogel for targeted drug delivery. Biomaterials 2013, 34(13):3523-3533.
51. Hölig P., Bach M., Völkel T., Nahde T., Hoffmann S., Müller R., et al. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng. Des. Sel 2004, 17(5):433-441.
52. Xiao K., Li Y., Lee J.S., Gonik A.M., Dong T., Fung G., et al. "OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res 2012, 72(8):2100-2110.
53. Liu Y., Gao F.-P., Zhang D., Fan Y.-S., Chen X.-G., Wang H. Molecular structural transformation regulated dynamic disordering of supramolecular vesicles as pH-responsive. J. Control. Release 2014, 173:140-147.
54. Wang L.M., Lin X.Y., Wang J., Hu Z.J., Ji Y.L., Hou S., et al. Novel insights into combating cancer chemotherapy resistance using a plasmonic nanocarrier: enhancing drug sensitiveness and accumulation simultaneously with localized mild photothermal stimulus of femtosecond pulsed laser. Adv. Funct. Mater 2014, 24(27):4229-4239.
55. Gatouillat G., Odot J., Balasse E., Nicolau C., Tosi P.F., Hickman D.T., et al. Immunization with liposome-anchored pegylated peptides modulates doxorubicin sensitivity in P-glycoprotein-expressing P388 cells. Cancer Lett 2007, 257(2):165-171.
56. Sinha R., Kim G.J., Nie S., Shin D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther 2006, 5(8):1909-1917.
57. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev 2008, 60:1615-1626.
58. Danhier F., Feron O., Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148(2):135-146.
59. Salehan M.R., Morse H.R. DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. Br. J. Biomed. Sci 2013, 70(1):31-40.
60. Wang K., Wu X., Wang J., Huang J. Cancer stem cell theory: therapeutic implications for nanomedicine. Int. J. Nanomedicine 2013, 8:899-908. 10.2147/IJN.S38641.
61. Burger J.A., Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009, 23(1):43-52. 10.1038/leu.2008.299.
62. Sioud M. Innate sensing of self and non-self RNAs by Toll-like receptors. Trends Mol. Med 2006, 12(4):167-176.
63. Goldsmith M., Mizrahy S., Peer D. Grand challenges in modulating the immune response with RNAi nanomedicines. Nanomedicine (Lond.) 2011, 6(10):1771-1785. 10.2217/nnm.11.162.
64. Da Silva C.G., Rueda F., Löwik C.W., Ossendorp F., Cruz L.J. Combinatorial prospects of nano-targeted chemoimmunotherapy. Biomaterials 2016, 83:308-320.
65. Mandal S., Eksteen-Akeroyd Z.H., Jacobs M.J., Hammink R., Koepf M., Lambeck A.J.A., et al. Therapeutic nanoworms: towards novel synthetic dendritic cells for immunotherapy. Chem. Sci 2013, 4:4168-4174.
66. Bindea G., Mlecnik B., Fridman W.H., Pages F., Galon J. Natural immunity to cancer in humans. Curr. Opin. Immunol 2010, 22:215-222.
67. Ferrone C., Dranoff G. Dual roles for immunity in gastrointestinal cancers. J. Clin. Oncol 2010, 28:4045-4051.
68. Nelson B.H. The impact of T-cell immunity on ovarian cancer outcomes. Immunol. Rev 2008, 222:101-116.
69. Kievit F.M., Stephen Z.R., Veiseh O., Arami H., Wang T., Lai V.P., et al. Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs. ACS Nano 2012, 6(3):2591-2601.
70. Feron O. Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol. Sci 2004, 25(10):536-542.
71. Siemann D.W., Bibby M.C., Dark G.G., Dicker A.P., Eskens F.A., Horsman M.R., et al. Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res 2005, 11(2 Pt 1):416-420.
72. Neri D., Bicknell R. Tumour vascular targeting. Nat. Rev. Cancer 2005, 5(6):436-446. Review.
73. Neri D., Carnemolla B., Nissim A., Leprini A., Querzè G., Balza E., et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat. Biotechnol 1997, 15(12):1271-1275.
74. Schliemann C., Neri D. Antibody-based targeting of the tumor vasculature. Biochim. Biophys. Acta 2007, 1776(2):175-192.
75. Leucuta S.E. Systemic and biophase bioavailability and pharmacokinetics of nanoparticulate drug delivery systems. Curr. Drug Deliv 2013, 10(2):208-240.
76. Fraley R., Papahadjopoulos D. Liposomes: the development of a new carrier system for introducing nucleic acid into plant and animal cells. Curr. Top. Microbiol. Immunol 1982, 96:171-191.
77. Geng Y., Dalhaimer P., Cai S., Tsal R., Tewari M., Minko T., et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol 2007, 2:249-255.
78. Cai S., Vijayan K., Cheng D., Lima E., Discher D. Micelles of different morphologies - advantages of worm-like filomicelles of peo-pcl in paclitaxel delivery. Pharm. Res 2007, 24:2099-2109.
79. Liu W., Zhou X., Mao Z., Yu D., Wang B., Gao C. Uptake of hydrogel particles with different stiffness and its influence on HepG2 cell functions. Soft Matter 2012, 8:9235-9245.
80. Zelikin A.N., Breheney K., Robert R., Tjipto E., Wark K. Cytotoxicity and internalization of polymer hydrogel capsules by mammalian cells. Biomacromolecules 2010, 11(8):2123-2129.
81. Shi S., Yang K., Hong H., Chen F., Valdovinos H.F., Goel S., et al. VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide in vivo. Biomaterials 2015, 39:39-46.
82. Wu Z., Zhan S., Fan W., Ding X., Wu X., Zhang W., et al. Peptide-mediated tumor targeting by a degradable nano gene delivery vector based on pluronic-modified polyethylenimine. Nanoscale Res. Lett 2016, 11(1):122.
83. Walther W., Schlag P.M. Current status of gene therapy for cancer. Curr. Opin. Oncol 2013, 25:659-664.
84. Somia N., Verma I.M. Gene therapy: trials and tribulations. Nat. Rev. Genet 2000, 1:91-99.
85. Verma I.M., Weitzman M.D. Gene therapy: twenty-first century medicine. Annu. Rev. Biochem 2005, 74:711-738.
86. Viiala N.O., Larsen S.R., Rasko J.E. Gene therapy for hemophilia: clinical trials and technical tribulations. Semin. Thromb. Hemost 2009, 35:81-92.
87. Verma I.M., Somia N. Gene therapy promise, problems and prospects. Nature 1997, 389:239-242.
88. Górecki D.C. Prospects and problems of gene therapy: an update. Expert Opin. Emerg. Drugs 2001, 6(2):187-198.
89. Cheng J., Tang X., Zhao J., Shi T., Zhao P., Lin C. Multifunctional cationic polyurethanes designed for non-viral cancer gene therapy. Acta Biomater 2016, 30:155-167.
90. Giacca M., Zacchigna S. Virus-mediated gene delivery for human gene therapy. J. Control. Release 2012, 161:377-388.
91. Yin H., Kanasty R.L., Eltoukhy A.A., Vegas A.J., Dorkin J.R., Anderson D.G. Nonviral vectors for gene-based therapy. Nat. Rev. Genet 2014, 15:541-555.
92. Suzuki R., Yamada Y., Harashima H. Development of small, homogeneous pDNA particles condensed with mono-cationic detergents and encapsulated in a multifunctional envelope-type nano device. Biol. Pharm. Bull 2008, 31(6):1237-1243.
93. Cai L.L., Liu P., Li X., Huang X., Ye Y.Q., Chen F.Y., et al. RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrinoverexpressing tumor cells. Int. J. Nanomedicine 2011, 6:3499-3508.
94. Hamano N., Negishi Y., Fujisawa A., Manandhar M., Sato H., Katagiri F., et al. Modification of the C16Y peptide on nanoparticles is an effective approach to target endothelial and cancer cells via the integrin receptor. Int. J. Pharm 2012, 428:114-117.
95. Xing H.B., Pan H.M., Fang Y., Zhou X.Y., Pan Q., Li D. Construction of a tumor cell-targeting non-viral gene delivery vector with polyethylenimine modified with RGD sequence-containing peptide. Oncol. Lett 2014, 7:487-492.
96. Gao Z., Zhang L., Sun Y. Nanotechnology applied to overcome tumor drug resistance. J. Control. Release 2012, 162:45-55.
97. Veiseh O., Gunn J.W., Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv. Drug Deliv. Rev 2010, 62:284-304.
98. Qiao Z.-Y., Qiao S.-L., Fan G., Fan Y.-S., Chen Y., Wang H. One-pot synthesis of pHsensitive poly(RGD-co-[small beta]-amino ester)s for targeted intracellular drug delivery. Polym. Chem 2014, 5:844-853.
99. Sun T.-M., Du J.-Z., Yao Y.-D., Mao C.-Q., Dou S., Huang S.-Y., et al. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 2011, 5:1483-1494.
100. Ali I., Rahis-Uddin, Salim K., Rather M.A., Wani W.A., Haque A. Advances in nano drugs for cancer chemotherapy. Curr. Cancer Drug Targets 2011, 11(2):135-146.
101. Su W., Zhang S., Li C., Hao X., Zhang J. Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer. Zhonghua Zhong Liu Za Zhi 2015, 37(5):379-382.
102. Zhao Y.Z., Chen L.J., Lin Q., Cai J., Yu W.Z., Zhao Y.P., et al. Using FUS induced BBB/BTB-opening technique combined with Doxorubicin liposomes to improve glioma-targeted inhibition. Oncotarget 2015, Epub 2 Sep 2015. 10.18632/oncotarget.5144.